iBio (IBIO) Income from Non-Controlling Interests (2016 - 2024)
iBio (IBIO) posted quarterly Income from Non-Controlling Interests of $11000.0 for Q1 2024, down 31.25% year-over-year from $16000.0 in Q2 2023, and down 15.38% quarter-over-quarter from $13000.0 in Q4 2023.
iBio (IBIO) Income from Non-Controlling Interests (2016 - 2024) Analysis & Trends
iBio (IBIO) has reported Income from Non-Controlling Interests for 9 consecutive years, with $11000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Income from Non-Controlling Interests fell 31.25% year-over-year to $11000.0; the TTM figure through Mar 2024 stood at $54000.0 (up 68.75% YoY), while the FY2023 annual figure was $49000.0, up 5000.0% from the prior year.
- Income from Non-Controlling Interests declined to $11000.0 in Q1 2024 per IBIO's latest filing, from $13000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $16000.0 in Q4 2022 and bottomed at -$13000.0 in Q4 2020.
- Historically, Income from Non-Controlling Interests has averaged $5000.0 across 5 years, with a median of $5000.0 in 2021.
- Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests slumped 600.0% — and 2021, when it surged 85.71%.
- iBio's Income from Non-Controlling Interests stood at -$13000.0 in 2020, then soared by 92.31% to -$1000.0 in 2021, then soared by 1700.0% to $16000.0 in 2022, then fell by 18.75% to $13000.0 in 2023, then decreased by 15.38% to $11000.0 in 2024.
- Business Quant data shows IBIO's Income from Non-Controlling Interests at $11000.0 in Q1 2024, $13000.0 in Q4 2023, and $14000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Jun 30, 2023 | 16,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | 16,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Dec 31, 2020 | -13,000.00 |
| Sep 30, 2020 | -7,000.00 |
| Jun 30, 2020 | -2,000.00 |
| Dec 31, 2019 | -2,000.00 |
| Sep 30, 2019 | -1,000.00 |
| Jun 30, 2019 | -1,000.00 |
| Mar 31, 2019 | -1,000.00 |
| Dec 31, 2018 | -1,000.00 |
| Sep 30, 2018 | -1,000.00 |
| Mar 31, 2018 | -1,000.00 |
| Dec 31, 2017 | -1,000.00 |